Jonathan Parker, DO
Family Medicine · Muscle Shoals, ALNPI 1710272265
Payments from drug & device makers
Across 535 payments — averaging $399.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$211K
- AbbVie$407
- Amgen$269
- Lilly USA, LLC$211
- GSK$170
- AstraZeneca$167
- plus $1K from 26 others
What the payments were for
- Consulting fees$6,3993%
- Speaking & faculty fees$192,34390%
- Travel & lodging$6,3463%
- Food & beverage$8,5534%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 357 | $211,182 |
| AbbVie(2 entities) | 41 | $407 |
| Amgen(2 entities) | 21 | $269 |
| Lilly USA, LLC | 13 | $211 |
| GSK | 13 | $170 |
| AstraZeneca | 9 | $167 |
| Boehringer Ingelheim | 12 | $166 |
| Corcept Therapeutics | 8 | $154 |
| Pfizer | 9 | $139 |
| Novartis | 8 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $91 |
| Astellas Pharma US Inc | 4 | $58 |
| Merck | 4 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Dexcom, Inc. | 3 | $45 |
| Antares Pharma, Inc. | 2 | $43 |
| Rhythm Pharmaceuticals, Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $38 |
| Johnson & Johnson | 3 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Bausch Health US, LLC | 1 | $20 |
| Medtronic | 1 | $18 |
| Abbott | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$213,658 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $270,703 |
| MounjaroTirzepatide | 221 | $250,834 |
| JardianceEmpagliflozin | 69 | $50,771 |
| TrulicityDulaglutide | 19 | $24,723 |
| EliquisApixaban | 31 | $19,823 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $16,658 |
| LinzessLinaclotide | 19 | $15,018 |
| FarxigaDapagliflozin Propanediol | 25 | $13,666 |
| VascepaIcosapent Ethyl | 11 | $7,787 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $7,046 |
| BelsomraSuvorexant | 11 | $5,095 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 13 | $3,121 |
| Metformin Hcl ErMetformin Hcl | 507 | $2,893 |
| Vilazodone Hcl | 15 | $2,679 |
| NovologInsulin Aspart | 11 | $2,346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $211 | $275,557240 claims |
| Novo NordiskOzempic, Novolog | $211,182 | $273,049256 claims |
| Boehringer IngelheimJardiance | $166 | $50,77169 claims |
| PfizerEliquis | $139 | $19,82331 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $407 | $17,16350 claims |
| GSKTrelegy Ellipta | $170 | $16,65827 claims |
| AstraZenecaFarxiga | $167 | $13,66625 claims |
| MerckBelsomra | $53 | $5,09511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Muscle Shoals
- Terence HartMuscle Shoals$323K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.